Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biocon Chief Sees Bright Future For Indian Pharma In Trump Era

Executive Summary

Biocon’s chair and managing director, Kiran Mazumdar-Shaw, tells Scrip she sees a strong partnering role for Indian firms in the Trump regime, but adds that “carte blanche” pricing that innovator companies enjoyed could come under check.

Advertisement

Related Content

Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel